If you or a loved one is taking Tysabri, understanding the difference between early symptoms and a confirmed diagnosis of progressive multifocal leukoencephalopathy (PML) is critical. The medical community has long recognized the need for clear communication about treatment risks, and this page clarifies what PML looks like versus how it is formally diagnosed.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. PML is a rare but devastating condition that typically occurs in immunocompromised individuals. The clinical presentation of PML can vary but often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is confirmed through brain imaging, typically MRI, and detection of JC virus DNA in cerebrospinal fluid. The disease is often fatal or leads to severe, permanent disability. The mechanism linking Tysabri to PML involves the drug's action on the immune system. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing them from crossing the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing the JC virus to reactivate and cause infection in the brain. Three key risk factors for developing PML while on Tysabri have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.
From a legal perspective, patients who develop PML after taking Tysabri may have grounds for a product liability claim. A key issue is the adequacy of warnings provided by the manufacturer. The FDA-mandated boxed warning and the TOUCH Prescribing Program are designed to inform patients and healthcare providers of the risks. However, questions may arise about whether the warnings were sufficiently clear or timely, especially for patients who developed PML before the risks were fully understood. Attorney considerations for affected patients include evaluating the timeline between Tysabri exposure and the onset of PML symptoms, as well as the presence of known risk factors. In New York, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury. For wrongful death claims, the statute is two years from the date of death. However, the discovery rule may apply, meaning the clock starts when the injury is discovered or reasonably should have been discovered. Given the latency of PML, which can develop months to years after starting Tysabri, determining the exact date of injury can be complex. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to understand their rights and the applicable deadlines. The timeline between Tysabri exposure and documented harm is critical in these cases. PML can occur after a few months of treatment or after several years, with longer treatment duration increasing risk. The FDA label notes that 'longer treatment duration, especially beyond 2 years' is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML may experience rapid neurological decline, and early diagnosis and discontinuation of Tysabri are essential for improving outcomes. However, even with prompt treatment, many patients suffer permanent disability or death.
The FDA Adverse Event Reporting System (FAERS) database lists numerous adverse events associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, and gait disturbance (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most frequently reported events, its severity makes it a critical safety concern. The boxed warning emphasizes that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, Tysabri-associated PML is a serious adverse event with a well-established mechanism and identifiable risk factors. The FDA has mandated strong warnings and a restricted distribution program to mitigate this risk. For patients in New York who have developed PML after taking Tysabri, legal action may be possible, but strict statute of limitations deadlines apply. Affected individuals should seek legal advice promptly to preserve their claims.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In New York, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury. For wrongful death claims, the statute is two years from the date of death. However, the discovery rule may apply, meaning the clock starts when the injury is discovered or reasonably should have been discovered. Given the latency of PML, it is crucial to consult an attorney promptly.
Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.